サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1441364

心臓マーカー検査の世界市場規模調査＆予測：製品タイプ別、バイオマーカータイプ別、疾患別、エンドユーザー別、地域別分析、2023-2030年

Global Cardiac Marker Testing Market Size Study & Forecast, by Product Type, by Biomarker Type, by Diseases, by End User, and Regional Analysis, 2023-2030

出版日
ページ情報
英文
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
心臓マーカー検査の世界市場規模調査＆予測：製品タイプ別、バイオマーカータイプ別、疾患別、エンドユーザー別、地域別分析、2023-2030年
出版日: 2024年02月20日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の心臓マーカー検査市場は、2022年に約40億2,000万米ドルと評価され、予測期間2023-2030年には9.4％以上の健全な成長率で成長すると予測されています。

心臓マーカー検査では、心臓に関連する状態に反応して血流に放出される特定の生体分子を分析し、心血管疾患の診断と評価に役立てています。これらのマーカーは、急性冠症候群、心臓発作、その他の心臓疾患の診断に役立ちます。検査は血液検査によってマーカー濃度を測定し、濃度が高いほど心筋障害を示します。心臓マーカー検査は、早期診断、リスク評価、治療モニタリング、急性心筋梗塞の除外や確認に不可欠です。心臓マーカー検査は心血管系医療において極めて重要な役割を果たしており、タイムリーな介入と患者の転帰改善に寄与しています。新規心臓バイオマーカーの同定に向けた臨床研究の増加、世界の高齢者人口の増加とそれに伴う心臓疾患の増加、心臓疾患の診断に向けた政府の団結した取り組み、官民組織による資金調達イニシアチブの拡大は、世界中で市場の需要を促進している最も顕著な要因です。

加えて、心血管疾患の急増は、心臓マーカー検査の需要に直接関連しており、その結果、市場の成長率は大幅に増加しています。世界保健機関（WHO）の報告によると、世界中で毎年推定1,790万人が死亡しており、心血管疾患（CVDs）は世界の主要な死亡原因です。また、心血管疾患による死亡の85％は心臓発作と脳卒中によるものです。CVDが依然として罹患率および死亡率の主要な原因であるため、これらの疾患を特定し管理するための診断ツールに対する需要は増加の一途をたどっています。さらに、虚血性心疾患（IHD）は、2020年7月Science誌のCureus Journal of Medicalに掲載された研究によると、世界の死亡の主な原因となっています。虚血性心疾患は世界で約1億2,600万人（10万人当たり1,655人）が罹患しており、これは全人口の約1.72％にあたる。2030年には、全世界で10万人当たり1,845人以上の虚血性心疾患が発症すると予測されています。さらに、心血管疾患のための新規心臓バイオマーカーに関する調査が進行中であり、POC（Point-of-Care）検査の需要が急増していることから、予測期間中にさまざまな有利な機会がもたらされます。しかし、サンプルの収集と保管に関する技術的な問題やバイオマーカーアッセイの検証に関連するいくつかの課題が、2023-2030年の予測期間を通じて市場の成長を妨げています。

心臓マーカー検査の世界市場調査において考慮した主要地域には、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカが含まれます。北米は、心血管疾患の症例が多いこと、心臓マーカー検査手技が増加していること、心臓バイオマーカー検査で強固なポートフォリオを持つ老舗企業が存在することから、2022年の市場を独占しました。さらに、新たな心臓バイオマーカーの探索に対する政府の支援は、同地域の心臓マーカー検査市場にさらなる機会を提供すると予想されます。一方、アジア太平洋地域は予測期間中に最も速いCAGRで成長すると予想されます。心血管疾患（CVD）の有病率の上昇、検査手順の急増、医療インフラの進歩、臨床検査室における高度なイムノアッセイ技術の広範な導入が、同地域全体の市場需要を大きく促進しています。さらに、アジア太平洋地域の心臓マーカー検査市場は、心臓マーカー用の検査製品を提供する現地メーカーの急増と、同地域の診断ラボのネットワーク拡大から恩恵を受ける見込みです。

本調査の目的は、近年のさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 心臓マーカー検査の世界市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 業界の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 心臓マーカー検査の世界市場力学

  • 心臓マーカー検査市場の影響分析（2020-2030年）
    • 市場促進要因
      • 心血管疾患の急増
      • 心疾患の診断に向けた政府の結束した取り組み
    • 市場の課題
      • サンプル採取と保管に関する技術的問題
      • バイオマーカーアッセイのバリデーションに関する課題
    • 市場機会
      • 心血管疾患の新規心臓バイオマーカーに関する継続的研究
      • ポイントオブケア（POC）検査に対する需要の高まり

第4章 世界の心臓マーカー検査市場産業分析

  • ポーターのファイブフォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターのファイブフォース影響分析
  • PEST分析
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 心臓マーカー検査の世界市場：製品タイプ別

  • 市場スナップショット
  • 心臓マーカー検査の世界市場：製品タイプ別、実績 - ポテンシャル分析
  • 心臓マーカー検査の世界市場：製品タイプ別推定・予測 2020-2030年
  • 心臓マーカー検査市場、サブセグメント分析
    • 試薬およびキット
    • 検査機器

第6章 心臓マーカー検査の世界市場：バイオマーカータイプ別

  • 市場スナップショット
  • 心臓マーカー検査の世界市場：バイオマーカータイプ別、実績 - ポテンシャル分析
  • 心臓マーカー検査の世界市場：バイオマーカータイプ別推定・予測 2020-2030年
  • 心臓マーカー検査市場、サブセグメント分析
    • トロポニンI・トロポニンT
    • クレアチンキナーゼ-MB（CK-MB）
    • 脳性ナトリウム利尿ペプチド（BnpまたはNt-Probnp）
    • ミオグロビン
    • 高感度CRP（hs-CRP）
    • その他の心臓バイオマーカー

第7章 心臓マーカー検査の世界市場：疾患別

  • 市場スナップショット
  • 心臓マーカー検査の世界市場：疾患別、実績 - ポテンシャル分析
  • 心臓マーカー検査の世界市場：疾患別推定・予測 2020-2030年
  • 心臓マーカー検査市場、サブセグメント分析
    • 心筋梗塞
    • うっ血性心不全
    • 急性冠症候群
    • アテローム性動脈硬化症
    • 虚血

第8章 心臓マーカー検査市場：エンドユーザー別

  • 市場スナップショット
  • 心臓マーカー検査の世界市場：エンドユーザー別、実績 - ポテンシャル分析
  • 心臓マーカー検査の世界市場：エンドユーザー別推定・予測2020-2030年
  • 心臓マーカー検査市場、サブセグメント分析
    • ラボ検査施設
    • ポイントオブケア検査施設
    • 学術機関

第9章 心臓マーカー検査の世界市場：地域別分析

  • 主要国
  • 主な新興国
  • 心臓マーカー検査市場、地域別市場スナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他中東とアフリカ

第10章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • F. Hoffmann-La Roche AG
      • 主要情報
      • 概要
      • 財務（データの入手可能性によります）
      • 製品概要
      • 最近の動向
    • Abbott Laboratories
    • Danaher Corporation
    • Siemens Healthineers AG
    • PerkinElmer, Inc.
    • BioMerieux SA
    • Becton, Dickinson and Company
    • Thermo Fisher Scientific Inc.
    • Bio-Rad Laboratories, Inc.
    • Tosoh Corporation

第11章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Cardiac Marker Testing Market, report scope
  • TABLE 2. Global Cardiac Marker Testing Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Cardiac Marker Testing Market estimates & forecasts by Product Type 2020-2030 (USD Billion)
  • TABLE 4. Global Cardiac Marker Testing Market estimates & forecasts by Biomarker Type 2020-2030 (USD Billion)
  • TABLE 5. Global Cardiac Marker Testing Market estimates & forecasts by Diseases 2020-2030 (USD Billion)
  • TABLE 6. Global Cardiac Marker Testing Market estimates & forecasts by End User 2020-2030 (USD Billion)
  • TABLE 7. Global Cardiac Marker Testing Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Cardiac Marker Testing Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Cardiac Marker Testing Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Cardiac Marker Testing Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Cardiac Marker Testing Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Cardiac Marker Testing Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Cardiac Marker Testing Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Cardiac Marker Testing Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. Global Cardiac Marker Testing Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. Global Cardiac Marker Testing Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 17. U.S. Cardiac Marker Testing Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 18. U.S. Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19. U.S. Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 20. Canada Cardiac Marker Testing Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 21. Canada Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. Canada Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 23. UK Cardiac Marker Testing Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 24. UK Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. UK Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 26. Germany Cardiac Marker Testing Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 27. Germany Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. Germany Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 29. France Cardiac Marker Testing Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 30. France Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. France Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 32. Italy Cardiac Marker Testing Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 33. Italy Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Italy Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 35. Spain Cardiac Marker Testing Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 36. Spain Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. Spain Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 38. RoE Cardiac Marker Testing Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 39. RoE Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. RoE Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 41. China Cardiac Marker Testing Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 42. China Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. China Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 44. India Cardiac Marker Testing Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 45. India Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. India Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 47. Japan Cardiac Marker Testing Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 48. Japan Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. Japan Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 50. South Korea Cardiac Marker Testing Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 51. South Korea Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. South Korea Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 53. Australia Cardiac Marker Testing Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 54. Australia Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. Australia Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 56. RoAPAC Cardiac Marker Testing Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 57. RoAPAC Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. RoAPAC Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 59. Brazil Cardiac Marker Testing Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 60. Brazil Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Brazil Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 62. Mexico Cardiac Marker Testing Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 63. Mexico Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. Mexico Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 65. RoLA Cardiac Marker Testing Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 66. RoLA Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. RoLA Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 68. Saudi Arabia Cardiac Marker Testing Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 69. South Africa Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 70. RoMEA Cardiac Marker Testing Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 71. List of secondary sources, used in the study of global Cardiac Marker Testing Market
  • TABLE 72. List of primary sources, used in the study of global Cardiac Marker Testing Market
  • TABLE 73. Years considered for the study
  • TABLE 74. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1. Global Cardiac Marker Testing Market, research methodology
  • FIG 2. Global Cardiac Marker Testing Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Cardiac Marker Testing Market, key trends 2022
  • FIG 5. Global Cardiac Marker Testing Market, growth prospects 2023-2030
  • FIG 6. Global Cardiac Marker Testing Market, porters 5 force model
  • FIG 7. Global Cardiac Marker Testing Market, pest analysis
  • FIG 8. Global Cardiac Marker Testing Market, value chain analysis
  • FIG 9. Global Cardiac Marker Testing Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Cardiac Marker Testing Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Cardiac Marker Testing Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Cardiac Marker Testing Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Cardiac Marker Testing Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Cardiac Marker Testing Market, regional snapshot 2020 & 2030
  • FIG 15. North America Cardiac Marker Testing Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Cardiac Marker Testing Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Cardiac Marker Testing Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Cardiac Marker Testing Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Cardiac Marker Testing Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Cardiac Marker Testing Market is valued at approximately USD 4.02 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 9.4% during the forecast period 2023-2030. Cardiac marker testing involves analyzing specific biomolecules released into the bloodstream in response to heart-related conditions, aiding in the diagnosis and assessment of cardiovascular diseases. These markers aid in diagnosing acute coronary syndromes, heart attacks, and other cardiac disorders. The testing is performed through blood tests to measure marker concentrations, with elevated levels indicating heart muscle damage. Cardiac marker testing is vital for early diagnosis, risk assessment, treatment monitoring, and ruling out or confirming acute myocardial infarction. It plays a pivotal role in cardiovascular medicine, contributing to timely interventions and improved patient outcomes. The rising clinical studies for the identification of novel cardiac biomarkers, the increase in geriatric population and subsequent escalation in heart conditions globally, cohesive government initiatives for the diagnosis of cardiac diseases, as well as growing funding initiatives from public and private organizations are the most prominent factors that are propelling the market demand across the globe.

In addition, the surge in incidences of cardiovascular diseases is directly associated with the demand for cardiac marker testing, which, in turn, augments the market growth at a substantial rate. The World Health Organization (WHO) reports that, with an estimated 17.9 million deaths worldwide each year, Cardiovascular Diseases (CVDs) are the world's leading cause of mortality. In addition, 85% of these fatalities from cardiovascular disease are caused by heart attacks and strokes. As CVDs remain a leading cause of morbidity and mortality, the demand for diagnostic tools to identify and manage these conditions continues to grow. Furthermore, Ischemic Heart Disease (IHD) is a major cause of mortality worldwide, as per a study published in the Cureus Journal of Medical in July 2020 Science. Ischemic heart disease affects around 126 million individuals globally (1,655 per 100,000), or about 1.72% of the total population. It is predicted that there are more than 1,845 instances of ischemic heart disease per 100,000 individuals globally by 2030. Moreover, the ongoing research on novel cardiac biomarkers for cardiovascular diseases, as well as the soaring demand for Point-of-Care (POC) testing presents various lucrative opportunities over the forecast years. However, the technical issues related to sample collection and storage and several challenges associated with biomarker assay validation are hindering market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Cardiac Marker Testing Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the high cases of cardiovascular diseases, a rise in cardiac marker testing procedures, and the presence of well-established entities with robust portfolios in cardiac biomarker testing. Additionally, government backing for the exploration of new cardiac biomarkers is anticipated to provide further opportunities to the Cardiac Marker Testing Market across the region. Whereas, Asia Pacific is expected to grow at the fastest CAGR over the forecast years. The rise in the prevalence of Cardiovascular Diseases (CVD), an upsurge in testing procedures, advancements in healthcare infrastructure, and the widespread incorporation of advanced immunoassay technology in clinical laboratories are significantly propelling the market demand across the region. Furthermore, the Cardiac Marker Testing Market in the Asia Pacific is poised to benefit from the proliferation of local manufacturers providing testing products for cardiac markers and the expanding network of diagnostic laboratories in the region.

Major market players included in this report are:

  • F. Hoffmann-La Roche AG
  • Abbott Laboratories
  • Danaher Corporation
  • Siemens Healthineers AG
  • PerkinElmer, Inc.
  • BioMerieux SA
  • Becton, Dickinson and Company
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • Tosoh Corporation

Recent Developments in the Market:

  • In October 2023, BD announced that the company had received the FDA's approval for the utilization of its BD Vacutainer Troponin I Ultra test in point-of-care settings. This approval designates the BD Vacutainer Troponin I Ultra test as the pioneering and sole FDA-approved troponin test for on-the-spot diagnosis of Acute Myocardial Infarction (AMI).

Global Cardiac Marker Testing Market Report Scope:

  • Historical Data - 2020 - 2021
  • Base Year for Estimation - 2022
  • Forecast period - 2023-2030
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered - Product Type, Biomarker Type, Diseases, End User, Region
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product Type:

  • Reagents and Kits
  • Instruments

By Biomarker Type:

  • Troponin I and T
  • Creatine kinase-MB(CK-MB)
  • Brain Natriuretic peptide (Bnp Or Nt-Probnp)
  • Myoglobin
  • High-sensitivity C-reactive protein (hs-CRP)
  • Other Cardiac Biomarkers

By Diseases:

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Ischemia

By End User:

  • Laboratory Testing Facilities
  • Point-Of-Care Testing Facilities
  • Academic Institutions

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Cardiac Marker Testing Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Cardiac Marker Testing Market, by Product Type, 2020-2030 (USD Billion)
    • 1.2.3. Cardiac Marker Testing Market, by Biomarker Type, 2020-2030 (USD Billion)
    • 1.2.4. Cardiac Marker Testing Market, by Diseases, 2020-2030 (USD Billion)
    • 1.2.5. Cardiac Marker Testing Market, by End User, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Cardiac Marker Testing Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Cardiac Marker Testing Market Dynamics

  • 3.1. Cardiac Marker Testing Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Surge in incidences of cardiovascular diseases
      • 3.1.1.2. Cohesive government initiatives for the diagnosis of cardiac diseases
    • 3.1.2. Market Challenges
      • 3.1.2.1. Technical issues related to sample collection and storage
      • 3.1.2.2. Challenges associated with biomarker assay validation
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Ongoing research on novel cardiac biomarkers for cardiovascular diseases
      • 3.1.3.2. Rising demand for point-of-care (POC) testing

Chapter 4. Global Cardiac Marker Testing Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Cardiac Marker Testing Market, by Product Type

  • 5.1. Market Snapshot
  • 5.2. Global Cardiac Marker Testing Market by Product Type, Performance - Potential Analysis
  • 5.3. Global Cardiac Marker Testing Market Estimates & Forecasts by Product Type 2020-2030 (USD Billion)
  • 5.4. Cardiac Marker Testing Market, Sub Segment Analysis
    • 5.4.1. Reagents and Kits
    • 5.4.2. Instruments

Chapter 6. Global Cardiac Marker Testing Market, by Biomarker Type

  • 6.1. Market Snapshot
  • 6.2. Global Cardiac Marker Testing Market by Biomarker Type, Performance - Potential Analysis
  • 6.3. Global Cardiac Marker Testing Market Estimates & Forecasts by Biomarker Type 2020-2030 (USD Billion)
  • 6.4. Cardiac Marker Testing Market, Sub Segment Analysis
    • 6.4.1. Troponin I and T
    • 6.4.2. Creatine kinase-MB(CK-MB)
    • 6.4.3. Brain Natriuretic peptide (Bnp Or Nt-Probnp)
    • 6.4.4. Myoglobin
    • 6.4.5. High-sensitivity C-reactive protein(hs-CRP)
    • 6.4.6. Other Cardiac Biomarkers

Chapter 7. Global Cardiac Marker Testing Market, by Diseases

  • 7.1. Market Snapshot
  • 7.2. Global Cardiac Marker Testing Market by Diseases, Performance - Potential Analysis
  • 7.3. Global Cardiac Marker Testing Market Estimates & Forecasts by Diseases 2020-2030 (USD Billion)
  • 7.4. Cardiac Marker Testing Market, Sub Segment Analysis
    • 7.4.1. Myocardial Infarction
    • 7.4.2. Congestive Heart Failure
    • 7.4.3. Acute Coronary Syndrome
    • 7.4.4. Atherosclerosis
    • 7.4.5. Ischemia

Chapter 8. Cardiac Marker Testing Market, by End User

  • 8.1. Market Snapshot
  • 8.2. Global Cardiac Marker Testing Market by End User, Performance - Potential Analysis
  • 8.3. Global Cardiac Marker Testing Market Estimates & Forecasts by End User 2020-2030 (USD Billion)
  • 8.4. Cardiac Marker Testing Market, Sub Segment Analysis
    • 8.4.1. Laboratory Testing Facilities
    • 8.4.2. Point-Of-Care Testing Facilities
    • 8.4.3. Academic Institutions

Chapter 9. Global Cardiac Marker Testing Market, Regional Analysis

  • 9.1. Top Leading Countries
  • 9.2. Top Emerging Countries
  • 9.3. Cardiac Marker Testing Market, Regional Market Snapshot
  • 9.4. North America Cardiac Marker Testing Market
    • 9.4.1. U.S. Cardiac Marker Testing Market
      • 9.4.1.1. Product Type breakdown estimates & forecasts, 2020-2030
      • 9.4.1.2. Biomarker Type breakdown estimates & forecasts, 2020-2030
      • 9.4.1.3. Diseases breakdown estimates & forecasts, 2020-2030
      • 9.4.1.4. End User breakdown estimates & forecasts, 2020-2030
    • 9.4.2. Canada Cardiac Marker Testing Market
  • 9.5. Europe Cardiac Marker Testing Market Snapshot
    • 9.5.1. U.K. Cardiac Marker Testing Market
    • 9.5.2. Germany Cardiac Marker Testing Market
    • 9.5.3. France Cardiac Marker Testing Market
    • 9.5.4. Spain Cardiac Marker Testing Market
    • 9.5.5. Italy Cardiac Marker Testing Market
    • 9.5.6. Rest of Europe Cardiac Marker Testing Market
  • 9.6. Asia-Pacific Cardiac Marker Testing Market Snapshot
    • 9.6.1. China Cardiac Marker Testing Market
    • 9.6.2. India Cardiac Marker Testing Market
    • 9.6.3. Japan Cardiac Marker Testing Market
    • 9.6.4. Australia Cardiac Marker Testing Market
    • 9.6.5. South Korea Cardiac Marker Testing Market
    • 9.6.6. Rest of Asia Pacific Cardiac Marker Testing Market
  • 9.7. Latin America Cardiac Marker Testing Market Snapshot
    • 9.7.1. Brazil Cardiac Marker Testing Market
    • 9.7.2. Mexico Cardiac Marker Testing Market
  • 9.8. Middle East & Africa Cardiac Marker Testing Market
    • 9.8.1. Saudi Arabia Cardiac Marker Testing Market
    • 9.8.2. South Africa Cardiac Marker Testing Market
    • 9.8.3. Rest of Middle East & Africa Cardiac Marker Testing Market

Chapter 10. Competitive Intelligence

  • 10.1. Key Company SWOT Analysis
    • 10.1.1. Company 1
    • 10.1.2. Company 2
    • 10.1.3. Company 3
  • 10.2. Top Market Strategies
  • 10.3. Company Profiles
    • 10.3.1. F. Hoffmann-La Roche AG
      • 10.3.1.1. Key Information
      • 10.3.1.2. Overview
      • 10.3.1.3. Financial (Subject to Data Availability)
      • 10.3.1.4. Product Summary
      • 10.3.1.5. Recent Developments
    • 10.3.2. Abbott Laboratories
    • 10.3.3. Danaher Corporation
    • 10.3.4. Siemens Healthineers AG
    • 10.3.5. PerkinElmer, Inc.
    • 10.3.6. BioMerieux SA
    • 10.3.7. Becton, Dickinson and Company
    • 10.3.8. Thermo Fisher Scientific Inc.
    • 10.3.9. Bio-Rad Laboratories, Inc.
    • 10.3.10. Tosoh Corporation

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption